SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549

                                    Form 8-K

                                 CURRENT REPORT

                Pursuant to Section 13 or 15(d) of the Securities
                  Exchange Act of 1934 Date of Report (Date of
                    earliest event reported): August 1, 2005

                              Scantek Medical, Inc.
        .................................................................
             (Exact name of registrant as specified in its charter)


            Delaware                  000-27592               84-1090126
 ...............................................................................
   (State or other jurisdiction      (Commission           (IRS Employer
        of incorporation)            File Number)         Identification No.)


                  4B WING DRIVE, CEDAR KNOLLS, NEW JERSEY 07927
 ...............................................................................
               (Address of principal executive offices) (Zip Code)

 Registrant's telephone number, including area code.............. (973) 401-0434


    .........................................................................
         (Former name or former address, if changed since last report.)

--------------------------------------------------------------------------------

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Item 8.01 Other Events.

      Scantek Medical,  Inc.  ("Scantek") has announced in a press release dated
August 1, 2005 that it  entered  into a Letter  of  Intent  with  Medical  Sales
Consultants,  GmbH ("MSC") pursuant to which Scantek has set forth its intention
of entering into a Distribution Agreement with MSC pursuant to which, subject to
the  terms  and  conditions  thereof,  Scantek  shall  grant  MSC an  exclusive,
perpetual  license  to  distribute  BreastCare(TM)/BreastAlert(TM)  Differential
Temperature  Sensor product  ("BreastCare(TM)")  in Austria,  Czech Republic and
Slovakia.

      The  Distribution   Agreement  shall  be  subject  to  certain  terms  and
conditions,  including,  but not limited to, payment of a purchase price for the
license and meeting certain minimum sales requirements. Scantek and MSC have not
yet entered into a  Distribution  Agreement and there can be no assurance that a
Distribution Agreement will be entered into.

Item 9.01 Financial Statement and Exhibits.

Exhibit 99.1-Scantek press release dated August 1, 2005.
--------------------------------------------------------------------------------


                                       2
<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                Scantek Medical, Inc.


Date:    August 1, 2005                         By: /s/ Zsigmond L. Sagi
                                                    ----------------------------
                                                    Dr. Zsigmond Sagi, President


                                       3
{"company-data": {"conformed-name": "SCANTEK MEDICAL INC", "cik": "0000926229", "assigned-sic": "5047", "irs-number": "841090126", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28824", "film-number": "05988667"}, "business-address": {"street1": "321 PALMER ROAD", "city": "DENVILLE", "state": "NJ", "zip": "079834", "phone": "9733665250"}, "mail-address": {"street1": "321 PALMER ROAD", "city": "DENVILLE", "state": "NJ", "zip": "07834"}}
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549

                                    Form 8-K

                                 CURRENT REPORT

                Pursuant to Section 13 or 15(d) of the Securities
                  Exchange Act of 1934 Date of Report (Date of
                    earliest event reported): August 1, 2005

                              Scantek Medical, Inc.
        .................................................................
             (Exact name of registrant as specified in its charter)

            Delaware                  000-27592               84-1090126
 ...............................................................................
   (State or other jurisdiction      (Commission           (IRS Employer
        of incorporation)            File Number)         Identification No.)

                  4B WING DRIVE, CEDAR KNOLLS, NEW JERSEY 07927
 ...............................................................................
               (Address of principal executive offices) (Zip Code)

 Registrant's telephone number, including area code.............. (973) 401-0434

    .........................................................................
         (Former name or former address, if changed since last report.)

--------------------------------------------------------------------------------

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.

      Scantek Medical,  Inc.  ("Scantek") has announced in a press release dated
August 1, 2005 that it  entered  into a Letter  of  Intent  with  Medical  Sales
Consultants,  GmbH ("MSC") pursuant to which Scantek has set forth its intention
of entering into a Distribution Agreement with MSC pursuant to which, subject to
the  terms  and  conditions  thereof,  Scantek  shall  grant  MSC an  exclusive,
perpetual  license  to  distribute  BreastCare(TM)/BreastAlert(TM)  Differential
Temperature  Sensor product  ("BreastCare(TM)")  in Austria,  Czech Republic and
Slovakia.

      The  Distribution   Agreement  shall  be  subject  to  certain  terms  and
conditions,  including,  but not limited to, payment of a purchase price for the
license and meeting certain minimum sales requirements. Scantek and MSC have not
yet entered into a  Distribution  Agreement and there can be no assurance that a
Distribution Agreement will be entered into.

Item 9.01 Financial Statement and Exhibits.

Exhibit 99.1-Scantek press release dated August 1, 2005.
--------------------------------------------------------------------------------

                                       2
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                Scantek Medical, Inc.

Date:    August 1, 2005                         By: /s/ Zsigmond L. Sagi
                                                    ----------------------------
                                                    Dr. Zsigmond Sagi, President

                                       3